| Minidoka Home Health | |
| 1218 9th Street, Suite 4, Rupert, Idaho 83350 | |
| (208) 436-9019 | |
| Name | Minidoka Home Health |
|---|---|
| Location | 1218 9th Street, Suite 4, Rupert, Idaho |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Medical Social Services Home Health Aide |
| Medicare ID | 137062 |
| Ownership Type | Government - State/county |
| Service Area Zip Codes | 83211, 83311, 83312, 83318, 83323, 83335, 83336, 83342, 83346, 83347, 83350 |
| NPI Number | 1205870219 |
| Organization Name | MINIDOKA MEMORIAL HOSPITAL |
| Doing Business As | MINIDOKA HOME HEALTH |
| Address | 1224 8th St, Rupert, ID 83350 |
| Phone Number | 208-436-0481 |
News Archive
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.
AdvaMed, the Advanced Medical Technology Association, has released an important new study that demonstrates the slow rate in growth in overall prices in the highly competitive medical technology sector.
A research group led by Kobe University Graduate School of Medicine Project Professor MORIOKA Ichirou and Professor IIJIMA Kazumoto (Department of Pediatrics) has suggested a potential method of screening for jaundice (hyperbilirubinemia), a cause of cerebral palsy and loss of hearing in preterm infants with kyperbilirubinemia, using painless dermal monitoring.
› Verified 1 days ago
| Quality Rating: |
News Archive
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.
AdvaMed, the Advanced Medical Technology Association, has released an important new study that demonstrates the slow rate in growth in overall prices in the highly competitive medical technology sector.
A research group led by Kobe University Graduate School of Medicine Project Professor MORIOKA Ichirou and Professor IIJIMA Kazumoto (Department of Pediatrics) has suggested a potential method of screening for jaundice (hyperbilirubinemia), a cause of cerebral palsy and loss of hearing in preterm infants with kyperbilirubinemia, using painless dermal monitoring.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 98.3 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 98.2 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.2 | 99.6 |
| How often the home health team checked patients for depression | 98.9 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 62 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 70.2 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 93.6 | 96.4 |
News Archive
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.
AdvaMed, the Advanced Medical Technology Association, has released an important new study that demonstrates the slow rate in growth in overall prices in the highly competitive medical technology sector.
A research group led by Kobe University Graduate School of Medicine Project Professor MORIOKA Ichirou and Professor IIJIMA Kazumoto (Department of Pediatrics) has suggested a potential method of screening for jaundice (hyperbilirubinemia), a cause of cerebral palsy and loss of hearing in preterm infants with kyperbilirubinemia, using painless dermal monitoring.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 70.5 | 79.6 |
| How often patients got better at getting in and out of bed | 72.1 | 81.1 |
| How often patients got better at bathing | 73.6 | 82.3 |
| How often patients’ breathing improved | 66.3 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 96.5 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 62.3 | 75 |
| How often home health patients had to be admitted to the hospital | 12.4 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 12 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 97.2 | 94 |
News Archive
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.
AdvaMed, the Advanced Medical Technology Association, has released an important new study that demonstrates the slow rate in growth in overall prices in the highly competitive medical technology sector.
A research group led by Kobe University Graduate School of Medicine Project Professor MORIOKA Ichirou and Professor IIJIMA Kazumoto (Department of Pediatrics) has suggested a potential method of screening for jaundice (hyperbilirubinemia), a cause of cerebral palsy and loss of hearing in preterm infants with kyperbilirubinemia, using painless dermal monitoring.
› Verified 1 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.
AdvaMed, the Advanced Medical Technology Association, has released an important new study that demonstrates the slow rate in growth in overall prices in the highly competitive medical technology sector.
A research group led by Kobe University Graduate School of Medicine Project Professor MORIOKA Ichirou and Professor IIJIMA Kazumoto (Department of Pediatrics) has suggested a potential method of screening for jaundice (hyperbilirubinemia), a cause of cerebral palsy and loss of hearing in preterm infants with kyperbilirubinemia, using painless dermal monitoring.
› Verified 1 days ago
The patient survey data of Minidoka Home Health is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 93 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 93 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 89 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 95 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 91 | 78 |
News Archive
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.
AdvaMed, the Advanced Medical Technology Association, has released an important new study that demonstrates the slow rate in growth in overall prices in the highly competitive medical technology sector.
A research group led by Kobe University Graduate School of Medicine Project Professor MORIOKA Ichirou and Professor IIJIMA Kazumoto (Department of Pediatrics) has suggested a potential method of screening for jaundice (hyperbilirubinemia), a cause of cerebral palsy and loss of hearing in preterm infants with kyperbilirubinemia, using painless dermal monitoring.
› Verified 1 days ago
Minidoka Home Health Location: 1218 9th Street, Suite 4, Rupert, Idaho 83350 Ratings: Phone: (208) 436-9019 |